Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France.
Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France.
Resuscitation. 2019 May;138:222-232. doi: 10.1016/j.resuscitation.2019.03.006. Epub 2019 Mar 15.
Early prognostication is a major challenge after out-of-hospital cardiac arrest (OHCA).
We hypothesized that a genome-wide analysis of blood gene expression could offer new prognostic tools and lines of research.
Sixty-nine patients were enrolled from an ancillary study of the clinical trial NCT00999583 that tested the effect of erythropoietin (EPO) after OHCA. Blood samples were collected in comatose survivors of OHCA at hospital admission and 1 and 3 days after resuscitation. Gene expression profiles were analyzed (Illumina HumanHT-12 V4 BeadChip; >34,000 genes). Patients were classified into two categories representing neurological favorable outcome (cerebral performance category [CPC] = 1-2) vs unfavorable outcome (CPC > 2) at Day 60 after OHCA. Differential and functional enrichment analyses were performed to compare transcriptomic profiles between these two categories.
Among the 69 enrolled patients, 33 and 36 patients were treated or not by EPO, respectively. Among them, 42% had a favorable neurological outcome in both groups. EPO did not affect the transcriptomic response at Day-0 and 1 after OHCA. In contrast, 76 transcripts differed at Day-0 between patients with unfavorable vs favorable neurological outcome. This signature persisted at Day-1 after OHCA. Functional enrichment analysis revealed a down-regulation of adaptive immunity with concomitant up-regulation of innate immunity and inflammation in patients with unfavorable vs favorable neurological outcome. The transcription of many genes of the HLA family was decreased in patients with unfavorable vs favorable neurological outcome. Concomitantly, neutrophil activation and inflammation were observed. Up-stream regulators analysis showed the implication of numerous factors involved in cell cycle and damages. A logistic regression including a set of genes allowed a reliable prediction of the clinical outcomes (specificity = 88%; Hit Rate = 83%).
A transcriptomic signature involving a counterbalance between adaptive and innate immune responses is able to predict neurological outcome very early after hospital admission after OHCA. This deserves confirmation in a larger population.
院外心脏骤停(OHCA)后早期预后是一个主要挑战。
我们假设对血液基因表达进行全基因组分析可以提供新的预后工具和研究方向。
从临床试验 NCT00999583 的辅助研究中纳入 69 例 OHCA 昏迷幸存者,该研究测试了 OHCA 后红细胞生成素(EPO)的疗效。在 OHCA 复苏后入院时、第 1 天和第 3 天采集血液样本。分析基因表达谱(Illumina HumanHT-12 V4 BeadChip;>34000 个基因)。将患者分为神经功能良好(脑功能分类 [CPC] = 1-2)和不良(CPC > 2)两组,在 OHCA 后 60 天进行分类。对这两组之间的转录组谱进行差异和功能富集分析。
在纳入的 69 例患者中,分别有 33 例和 36 例接受或未接受 EPO 治疗。其中,两组各有 42%的患者神经功能良好。EPO 对 OHCA 后第 0 天和第 1 天的转录组反应没有影响。相反,在第 0 天,预后不良和预后良好的患者之间有 76 个转录本存在差异。该特征在 OHCA 后第 1 天仍然存在。功能富集分析显示,与预后良好的患者相比,预后不良的患者适应性免疫下调,固有免疫和炎症上调。与预后良好的患者相比,预后不良的患者 HLA 家族的许多基因转录减少。同时观察到中性粒细胞的激活和炎症。上游调控因子分析显示,许多涉及细胞周期和损伤的因子都有参与。包括一组基因的逻辑回归可以可靠地预测临床结局(特异性=88%;命中率=83%)。
涉及适应性和固有免疫反应之间平衡的转录组特征能够在 OHCA 后入院早期非常准确地预测神经功能结局。这需要在更大的人群中进行验证。